• Krystal Biotech EVP, General Counsel Thomas John Charles sold 642 common shares on May 26, 2026.
• Shares sold at USD 302.03 each; post-transaction beneficial ownership reported as 0 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002114900-26-000006), on May 27, 2026, and is solely responsible for the information contained therein.